ATA Stock

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Atara's active Investigational New Drug (IND) applications. These INDs include the EBVALLOTM (tabelecleucel) program as monothe.

BEIJING, Dec. 03, 2024 (GLOBE NEWSWIRE) -- ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity, today announced two updates regarding its compliance status of continued listing requirements under The Nasdaq Stock Market LLC (“Nasdaq”) Listing Rules.

NEW YORK , Nov. 4, 2024 /PRNewswire/ -- Baird Medical (Nasdaq: BDMD), a leader in minimally invasive microwave ablation (MWA) technology, proudly participated in the 2024 American Thyroid Association (ATA) Annual Meeting. This year's event marked a milestone for Baird Medical, as it attracted significant interest from physicians and researchers worldwide, including attendees from the U.S., Europe, and South America.

BEIJING, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ATA Creativity Global ("ACG" or the "Company", Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity, today announced that it will release financial results for the third quarter and nine-month periods ended September 30, 2024, after the close of the stock market on Thursday, November 7, 2024.

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented.

NEW YORK , Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices in China, which recently expanded into the U.S. market following its U.S. FDA 510(k) clearances, today announced its participation in the upcoming American Thyroid Association (ATA) Annual Meeting.